GUFICBIO vs ZYDUSLIFE: Stock Comparison

Gufic Biosciences Limited vs Zydus Lifesciences Ltd

Live data: 22 July 2026, 2:41 PM IST • Source: NSE and company filings

Zydus Lifesciences Ltd is the larger company by market capitalisation. Gufic Biosciences Limited shows faster revenue growth, while Zydus Lifesciences Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Gufic Biosciences Limited and Zydus Lifesciences Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, GUFICBIO is more favourable on 4 of 13 scored metrics and ZYDUSLIFE on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ZYDUSLIFE is the larger company
₹1.12 L Cr vs ₹3,849 Cr
P/E Ratio
ZYDUSLIFE has a lower P/E
22.82x vs 62.05x
P/B Ratio
ZYDUSLIFE has a lower P/B
4.24x vs 5.99x
EPS
ZYDUSLIFE has higher earnings per share
₹50.1 vs ₹6.42
Dividend Yield
ZYDUSLIFE has a higher dividend yield
0.09% vs 0.03%
Revenue Growth (TTM YoY)
GUFICBIO has faster revenue growth
22.8% vs 16.2%
EPS Growth (TTM YoY)
GUFICBIO has faster EPS growth
183.1% vs 8.7%
Qtr Sales Growth
GUFICBIO has stronger quarterly sales growth
22.8% vs 16.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGUFICBIOZYDUSLIFE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGUFICBIOZYDUSLIFE
Live Price₹384.6₹1,119.9
Day Change-3.05%-2.03%
Volume35,31112.87 L
52-Week High₹448₹1,181.5
52-Week Low₹268₹835.5
Distance from 52W High-14.15%-5.21%

Valuation

MetricGUFICBIOZYDUSLIFE
Market Cap₹3,849 Cr₹1.12 L Cr
P/E Ratio62.05x22.82x
P/B Ratio5.99x4.24x
EPS₹6.42₹50.1
Book Value₹66.2₹269
Dividend Yield0.03%0.09%

Growth

MetricGUFICBIOZYDUSLIFE
Revenue Growth (TTM YoY)22.8%16.2%
EPS Growth (TTM YoY)183.1%8.7%
Qtr Sales Growth22.8%16.2%
Qtr Profit Growth184%21.9%

Profitability & Leverage

MetricGUFICBIOZYDUSLIFE
ROE10.1%21.2%
ROCE12.3%21.1%
Net Margin6.8%18.36%
Operating Margin16%31.2%
Debt to Equity0.61x0.46x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricGUFICBIOZYDUSLIFE
Promoter Holding72.5%75.01% 0.01 pp
FII Holding0.42% 0.02 pp6.88% 0.07 pp
DII Holding3.83% 0.09 pp11.27% 0.07 pp
Public Holding23.24% 0.08 pp6.83% 0.03 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Gufic Biosciences Limited and Zydus Lifesciences Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.